

### MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/11/2011; page 1

Suggested Formula	Sodium Acetate 2 mEq/mL Injection (Solution, 100 mL)	FIN	F 004 802
----------------------	--	-----	-----------

## SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC#	Supplier	Lot Number	Expiry Date
Sodium Acetate (Anhydrous), USP	16.406	g				
Sterile Water For Injection, USP	80.0	mL				
Sterile Water For Injection, USP	q.s. to 100.0	mL				
Acetic Acid 25% Solution	As required					

## **SPECIAL PREPARATORY CONSIDERATIONS**

Ingredient-Specific Information	
Hygroscopic (protect from hun	nidity whenever possible): Sodium Acetate
Suggested Preparatory Guidelines	
Non-Sterile Preparat	tion Sterile Preparation
Processing Error / Testing Considerations:	To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within <i>USP 797</i> . Only trained and qualified personnel must prepare this formula.
	All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.
	Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.
	Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.
	Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/11/2011; page 2

Suggested Formula	Sodium Acetate 2 mEq/mL Injection (Solution, 100 mL)	FIN	F 004 802
----------------------	--	-----	-----------

# **SUGGESTED PREPARATION (for 100 mL)**

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Sodium Acetate (Anhydrous), USP §	16.406	g			
Sterile Water For Injection, USP §	80.0	mL			
Sterile Water For Injection, USP §	q.s. to 100.0	mL	<b>©</b>		
Acetic Acid 25% Solution §	As required				

\* Takes into account increased batch size conversions and density conversions, if required.

IMPORTANT: Do not allow the pH to fall below 6.0.

§ Weigh / measure just prior to use.

	Preparatory Instruction
	IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique
1.	Equipment sterilization:
	Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.
2.	Powder to medium integration:
	A. Incrementally add the Sodium Acetate to the Sterile Water for Injection (80.0 mL <i>plus</i> processing error adjustments).
	Specifications: Continuously mix until all solid particles have completely dissolved.
	End result: Homogeneous liquid-like solution.
3.	pH testing:
	A. Draw an appropriate amount of the mixture (Step 2A).
	B. Test the pH of the sample. It should lie between 6.0 and 7.0.
	C. If the pH > 7.0, carefully add, in a dropwise fashion, the Acetic Acid 25% Solution to the mixture:
	<ol> <li>Draw and transfer 1 or 2 drops of the Acetic Acid 25% Solution to the mixture.</li> <li>Stir for at least 5 minutes to evenly disperse the Acetic Acid 25% Solution.</li> <li>Re-test the pH.</li> <li>Continue to add the Acetic Acid 25% Solution until the pH of 6.0 and 7.0 is obtained.</li> </ol>
	1



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/11/2011; page 3

Suggested Formula	Sodium Acetate 2 mEq/mL Injection (Solution, 100 mL)	FIN	F 004 802
----------------------	--	-----	-----------

## 4. **Filling to volume:**

A. Add additional Sterile Water For Injection to the above mixture to fill to the required batch size (100.0 mL *plus* processing error adjustments).

Specifications: Continuously mix.

End result: Homogeneous liquid-like solution.

### 5. Filtering and transferring:

Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.

## 6. Filter integrity test:

Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

## 7. **Sterility testing:**

Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.



TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/11/2011; page 4

Suggested Formula	Sodium Acetate 2 mEq/mL Injection (Solution, 100 mL)	FIN	F 004 802	
----------------------	--	-----	-----------	--

# **SUGGESTED PRESENTATION**

GGESTED PRI	LOLIN	TATION				
Estimated Beyond- Use Date		14 days, refrigerated as per USP 797. BUD based on a successful sterility and endotoxin test result.	Packag Requireme		Sterile, tightly closed unit dose injection vials.	
	1	Use as directed. Do not exceed place.	prescribed	7	Do not use if discolored.	
	2	Keep out of reach of children.		8	Discard in the presence of particulate matter.	
Auxiliary Labels	3	Keep refrigerated. Do not freeze.		9	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	
	4	Keep in a dry place.		10	Equilibrate to room temperature before use.	
	5	Preservative free solution, si only. Discard any unused porti		11	Discard container after use.	
	6	Hypertonic solution, inject slov	wly.	12	It must not be administered undiluted.	
Pharmacist Instructions  Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.  IMPORTANT: Using proper aseptic techniques, one must dilute the compounded product to the appropriate concentrations with the appropriate sterile diluent prior to intravenous injection. Also it must be administered accordingly as determined by the prescribing physician.  NOTE: Once diluted it must be used immediately and any unused portion must be discarded.						
Patient Instructions	Contact your pharmacist in the event of adverse reactions					



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/11/2011; page 5

Suggested Formula	Sodium Acetate 2 mEq/mL Injection (Solution, 100 mL)	FIN	F 004 802
----------------------	--	-----	-----------

#### REFERENCES

1.	Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 313.
2.	Sodium Acetate. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 6 <sup>th</sup> Edition. American Pharmaceutical Association; 2009. 620.
3.	Sodium Acetate. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition.</i> London, England: The Pharmaceutical Press; 2009: 1673.
4.	Sodium Acetate (Monograph). In: O'Neil MJ. <i>The Merck Index 14<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #8571.
5.	Sodium Acetate (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 3561.
6.	Chapter 18: Tonicity, Osmoticity, Osmolaltiy and Osmolarity. In: D.B Troy. <i>Remington: The Science and Practice of Pharmacy</i> , 21st Edition. Baltimore, MD: Lippincott Williams & Wilkins; 2006: 250~265.
7.	Chapter 8: Buffered and Isotonic Solutions. In: Martin, A. <i>Physical Pharmacy, Fourth Edition</i> . Philadelphia, PA: Lipponcott Williams & Wilkins; 1993: 169~189.
8.	USP <797>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 318.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.